nodes	percent_of_prediction	percent_of_DWPC	metapath
Furosemide—CA7—colon cancer	0.533	1	CbGaD
Furosemide—PGD—Methotrexate—colon cancer	0.101	0.355	CbGbCtD
Furosemide—ABCC2—Irinotecan—colon cancer	0.0312	0.11	CbGbCtD
Furosemide—SLC22A11—Methotrexate—colon cancer	0.0298	0.105	CbGbCtD
Furosemide—ABCC2—Vincristine—colon cancer	0.0273	0.0963	CbGbCtD
Furosemide—ALB—Irinotecan—colon cancer	0.0195	0.0687	CbGbCtD
Furosemide—ALB—Fluorouracil—colon cancer	0.0187	0.0659	CbGbCtD
Furosemide—SLC22A8—Methotrexate—colon cancer	0.0174	0.0612	CbGbCtD
Furosemide—ABCC2—Methotrexate—colon cancer	0.0165	0.0583	CbGbCtD
Furosemide—SLC22A6—Methotrexate—colon cancer	0.0121	0.0427	CbGbCtD
Furosemide—ALB—Methotrexate—colon cancer	0.0103	0.0363	CbGbCtD
Furosemide—CA14—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00999	0.119	CbGpPWpGaD
Furosemide—CA6—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00974	0.116	CbGpPWpGaD
Furosemide—CA5A—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00974	0.116	CbGpPWpGaD
Furosemide—CA5B—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00909	0.108	CbGpPWpGaD
Furosemide—CA12—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00842	0.1	CbGpPWpGaD
Furosemide—CA4—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00672	0.0797	CbGpPWpGaD
Furosemide—CA2—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00644	0.0765	CbGpPWpGaD
Furosemide—CA1—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00617	0.0733	CbGpPWpGaD
Furosemide—CA9—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00543	0.0644	CbGpPWpGaD
Furosemide—ABCC2—bile—colon cancer	0.0034	0.0988	CbGeAlD
Furosemide—Indapamide—CA7—colon cancer	0.00244	0.5	CrCbGaD
Furosemide—Bumetanide—CA7—colon cancer	0.00214	0.439	CrCbGaD
Furosemide—CA9—gall bladder—colon cancer	0.00196	0.0568	CbGeAlD
Furosemide—CA7—renal system—colon cancer	0.00107	0.0311	CbGeAlD
Furosemide—ALB—gall bladder—colon cancer	0.00101	0.0293	CbGeAlD
Furosemide—CA5A—liver—colon cancer	0.000982	0.0285	CbGeAlD
Furosemide—CA7—digestive system—colon cancer	0.000876	0.0255	CbGeAlD
Furosemide—SLC12A1—epithelium—colon cancer	0.000862	0.025	CbGeAlD
Furosemide—SLC22A11—renal system—colon cancer	0.000822	0.0239	CbGeAlD
Furosemide—SLC12A1—renal system—colon cancer	0.000799	0.0232	CbGeAlD
Furosemide—SLCO2A1—epithelium—colon cancer	0.000795	0.0231	CbGeAlD
Furosemide—CA9—digestive system—colon cancer	0.00077	0.0224	CbGeAlD
Furosemide—CA2—gall bladder—colon cancer	0.000743	0.0216	CbGeAlD
Furosemide—SLCO2A1—renal system—colon cancer	0.000738	0.0214	CbGeAlD
Furosemide—ABCC2—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000699	0.00829	CbGpPWpGaD
Furosemide—CA12—renal system—colon cancer	0.000694	0.0202	CbGeAlD
Furosemide—PGD—smooth muscle tissue—colon cancer	0.000683	0.0198	CbGeAlD
Furosemide—SLC22A11—digestive system—colon cancer	0.000675	0.0196	CbGeAlD
Furosemide—PGD—renal system—colon cancer	0.000657	0.0191	CbGeAlD
Furosemide—CA12—digestive system—colon cancer	0.000569	0.0165	CbGeAlD
Furosemide—CA1—renal system—colon cancer	0.00055	0.016	CbGeAlD
Furosemide—PGD—lymphoid tissue—colon cancer	0.000546	0.0159	CbGeAlD
Furosemide—CA14—liver—colon cancer	0.000544	0.0158	CbGeAlD
Furosemide—PGD—digestive system—colon cancer	0.000539	0.0157	CbGeAlD
Furosemide—SLCO2A1—vagina—colon cancer	0.000534	0.0155	CbGeAlD
Furosemide—SLC22A11—liver—colon cancer	0.000503	0.0146	CbGeAlD
Furosemide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EP300—colon cancer	0.000498	0.00591	CbGpPWpGaD
Furosemide—PGD—bone marrow—colon cancer	0.000497	0.0144	CbGeAlD
Furosemide—PGD—Carbohydrate metabolism—CHST5—colon cancer	0.000488	0.00579	CbGpPWpGaD
Furosemide—PGD—vagina—colon cancer	0.000476	0.0138	CbGeAlD
Furosemide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—VEGFA—colon cancer	0.000472	0.0056	CbGpPWpGaD
Furosemide—CA2—embryo—colon cancer	0.000471	0.0137	CbGeAlD
Furosemide—SLC22A8—renal system—colon cancer	0.000464	0.0135	CbGeAlD
Furosemide—CA1—lymphoid tissue—colon cancer	0.000457	0.0133	CbGeAlD
Furosemide—ABCC2—renal system—colon cancer	0.000453	0.0132	CbGeAlD
Furosemide—CA1—digestive system—colon cancer	0.000451	0.0131	CbGeAlD
Furosemide—CA5B—vagina—colon cancer	0.000451	0.0131	CbGeAlD
Furosemide—SLCO2A1—liver—colon cancer	0.000451	0.0131	CbGeAlD
Furosemide—CA4—renal system—colon cancer	0.00043	0.0125	CbGeAlD
Furosemide—CA1—bone marrow—colon cancer	0.000416	0.0121	CbGeAlD
Furosemide—PGD—liver—colon cancer	0.000402	0.0117	CbGeAlD
Furosemide—CA2—epithelium—colon cancer	0.000384	0.0112	CbGeAlD
Furosemide—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000382	0.00454	CbGpPWpGaD
Furosemide—ABCC2—digestive system—colon cancer	0.000371	0.0108	CbGeAlD
Furosemide—CA2—smooth muscle tissue—colon cancer	0.00037	0.0108	CbGeAlD
Furosemide—CA2—renal system—colon cancer	0.000356	0.0104	CbGeAlD
Furosemide—CA9—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000356	0.00423	CbGpPWpGaD
Furosemide—CA4—digestive system—colon cancer	0.000353	0.0102	CbGeAlD
Furosemide—SLC22A5—renal system—colon cancer	0.000351	0.0102	CbGeAlD
Furosemide—SLCO2A1—lymph node—colon cancer	0.000346	0.01	CbGeAlD
Furosemide—CA1—liver—colon cancer	0.000336	0.00977	CbGeAlD
Furosemide—CA4—bone marrow—colon cancer	0.000325	0.00944	CbGeAlD
Furosemide—ABCC2—Irinotecan Pathway—APC—colon cancer	0.000322	0.00382	CbGpPWpGaD
Furosemide—PGD—lymph node—colon cancer	0.000308	0.00895	CbGeAlD
Furosemide—CA2—lymphoid tissue—colon cancer	0.000296	0.0086	CbGeAlD
Furosemide—ALB—liver—colon cancer	0.000295	0.00858	CbGeAlD
Furosemide—Bumetanide—PTGS2—colon cancer	0.000294	0.0603	CrCbGaD
Furosemide—CA2—digestive system—colon cancer	0.000292	0.0085	CbGeAlD
Furosemide—CA5B—lymph node—colon cancer	0.000292	0.00848	CbGeAlD
Furosemide—SLC22A5—digestive system—colon cancer	0.000288	0.00836	CbGeAlD
Furosemide—ABCC2—liver—colon cancer	0.000277	0.00804	CbGeAlD
Furosemide—CA2—bone marrow—colon cancer	0.000269	0.00783	CbGeAlD
Furosemide—Photosensitivity reaction—Vincristine—colon cancer	0.000269	0.00449	CcSEcCtD
Furosemide—Mental disability—Capecitabine—colon cancer	0.000266	0.00443	CcSEcCtD
Furosemide—CA2—vagina—colon cancer	0.000258	0.0075	CbGeAlD
Furosemide—CA1—lymph node—colon cancer	0.000258	0.00749	CbGeAlD
Furosemide—Thrombophlebitis—Capecitabine—colon cancer	0.000257	0.00428	CcSEcCtD
Furosemide—Diabetes mellitus—Capecitabine—colon cancer	0.000256	0.00426	CcSEcCtD
Furosemide—SLC22A5—vagina—colon cancer	0.000254	0.00738	CbGeAlD
Furosemide—Polyuria—Capecitabine—colon cancer	0.000253	0.00422	CcSEcCtD
Furosemide—Photosensitivity—Capecitabine—colon cancer	0.000253	0.00422	CcSEcCtD
Furosemide—Swelling—Capecitabine—colon cancer	0.000252	0.0042	CcSEcCtD
Furosemide—Sweating—Vincristine—colon cancer	0.000252	0.0042	CcSEcCtD
Furosemide—Renal failure—Irinotecan—colon cancer	0.000252	0.00419	CcSEcCtD
Furosemide—Photosensitivity reaction—Fluorouracil—colon cancer	0.000251	0.00418	CcSEcCtD
Furosemide—Deafness—Capecitabine—colon cancer	0.000249	0.00414	CcSEcCtD
Furosemide—Vascular purpura—Capecitabine—colon cancer	0.000249	0.00414	CcSEcCtD
Furosemide—Haemolytic anaemia—Capecitabine—colon cancer	0.000246	0.00411	CcSEcCtD
Furosemide—Hyperuricaemia—Methotrexate—colon cancer	0.000246	0.0041	CcSEcCtD
Furosemide—Sweating—Irinotecan—colon cancer	0.000246	0.00409	CcSEcCtD
Furosemide—Dermatitis exfoliative—Capecitabine—colon cancer	0.000236	0.00393	CcSEcCtD
Furosemide—Thirst—Capecitabine—colon cancer	0.000234	0.00389	CcSEcCtD
Furosemide—Vasculitis—Methotrexate—colon cancer	0.000234	0.00389	CcSEcCtD
Furosemide—Urinary tract disorder—Vincristine—colon cancer	0.000233	0.00388	CcSEcCtD
Furosemide—Dermatitis bullous—Capecitabine—colon cancer	0.000233	0.00388	CcSEcCtD
Furosemide—Blood uric acid increased—Methotrexate—colon cancer	0.000232	0.00387	CcSEcCtD
Furosemide—Urethral disorder—Vincristine—colon cancer	0.000232	0.00386	CcSEcCtD
Furosemide—Purpura—Capecitabine—colon cancer	0.000231	0.00385	CcSEcCtD
Furosemide—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.00023	0.00274	CbGpPWpGaD
Furosemide—Agranulocytosis—Fluorouracil—colon cancer	0.000229	0.00381	CcSEcCtD
Furosemide—Lethargy—Capecitabine—colon cancer	0.000227	0.00378	CcSEcCtD
Furosemide—ALB—lymph node—colon cancer	0.000226	0.00658	CbGeAlD
Furosemide—Hyponatraemia—Capecitabine—colon cancer	0.000223	0.00372	CcSEcCtD
Furosemide—CA9—HIF-1-alpha transcription factor network—ABCB1—colon cancer	0.000222	0.00264	CbGpPWpGaD
Furosemide—Visual impairment—Irinotecan—colon cancer	0.000222	0.00369	CcSEcCtD
Furosemide—CA9—Cellular response to hypoxia—EP300—colon cancer	0.00022	0.00261	CbGpPWpGaD
Furosemide—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.00022	0.00261	CbGpPWpGaD
Furosemide—CA2—liver—colon cancer	0.000218	0.00633	CbGeAlD
Furosemide—SLC22A5—liver—colon cancer	0.000214	0.00623	CbGeAlD
Furosemide—Angiopathy—Vincristine—colon cancer	0.000214	0.00357	CcSEcCtD
Furosemide—Aplastic anaemia—Methotrexate—colon cancer	0.000214	0.00357	CcSEcCtD
Furosemide—Irritability—Capecitabine—colon cancer	0.000212	0.00354	CcSEcCtD
Furosemide—ABCC2—lymph node—colon cancer	0.000212	0.00616	CbGeAlD
Furosemide—Urinary retention—Capecitabine—colon cancer	0.000212	0.00352	CcSEcCtD
Furosemide—ABCC2—ABC-family proteins mediated transport—ABCB1—colon cancer	0.00021	0.00249	CbGpPWpGaD
Furosemide—Angiopathy—Irinotecan—colon cancer	0.000209	0.00348	CcSEcCtD
Furosemide—Blood creatinine increased—Capecitabine—colon cancer	0.000208	0.00347	CcSEcCtD
Furosemide—CA9—Cellular response to hypoxia—VEGFA—colon cancer	0.000208	0.00247	CbGpPWpGaD
Furosemide—Immune system disorder—Irinotecan—colon cancer	0.000208	0.00346	CcSEcCtD
Furosemide—Dehydration—Capecitabine—colon cancer	0.000207	0.00345	CcSEcCtD
Furosemide—Urine output increased—Methotrexate—colon cancer	0.000206	0.00344	CcSEcCtD
Furosemide—Bladder pain—Methotrexate—colon cancer	0.000206	0.00344	CcSEcCtD
Furosemide—Arrhythmia—Irinotecan—colon cancer	0.000205	0.00342	CcSEcCtD
Furosemide—Orthostatic hypotension—Capecitabine—colon cancer	0.000203	0.00338	CcSEcCtD
Furosemide—CA14—Metabolism—CA7—colon cancer	0.000203	0.00241	CbGpPWpGaD
Furosemide—Hypokalaemia—Capecitabine—colon cancer	0.000203	0.00337	CcSEcCtD
Furosemide—CA4—lymph node—colon cancer	0.000201	0.00585	CbGeAlD
Furosemide—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.0002	0.00334	CcSEcCtD
Furosemide—CA6—Metabolism—CA7—colon cancer	0.000198	0.00235	CbGpPWpGaD
Furosemide—CA5A—Metabolism—CA7—colon cancer	0.000198	0.00235	CbGpPWpGaD
Furosemide—Flatulence—Irinotecan—colon cancer	0.000197	0.00329	CcSEcCtD
Furosemide—Arrhythmia—Fluorouracil—colon cancer	0.000197	0.00328	CcSEcCtD
Furosemide—Muscular weakness—Capecitabine—colon cancer	0.000196	0.00327	CcSEcCtD
Furosemide—Abdominal distension—Capecitabine—colon cancer	0.000194	0.00322	CcSEcCtD
Furosemide—Muscle spasms—Irinotecan—colon cancer	0.000192	0.00321	CcSEcCtD
Furosemide—Erythema—Fluorouracil—colon cancer	0.000192	0.00319	CcSEcCtD
Furosemide—Thrombophlebitis—Methotrexate—colon cancer	0.000191	0.00319	CcSEcCtD
Furosemide—PGD—Metabolism—CA7—colon cancer	0.000191	0.00227	CbGpPWpGaD
Furosemide—Diabetes mellitus—Methotrexate—colon cancer	0.00019	0.00317	CcSEcCtD
Furosemide—Anaemia—Vincristine—colon cancer	0.00019	0.00316	CcSEcCtD
Furosemide—Agitation—Vincristine—colon cancer	0.000189	0.00315	CcSEcCtD
Furosemide—Polyuria—Methotrexate—colon cancer	0.000189	0.00314	CcSEcCtD
Furosemide—Photosensitivity—Methotrexate—colon cancer	0.000189	0.00314	CcSEcCtD
Furosemide—Anaemia—Irinotecan—colon cancer	0.000185	0.00308	CcSEcCtD
Furosemide—CA5B—Metabolism—CA7—colon cancer	0.000185	0.00219	CbGpPWpGaD
Furosemide—Vertigo—Vincristine—colon cancer	0.000185	0.00308	CcSEcCtD
Furosemide—Leukopenia—Vincristine—colon cancer	0.000184	0.00307	CcSEcCtD
Furosemide—Vision blurred—Fluorouracil—colon cancer	0.000181	0.00301	CcSEcCtD
Furosemide—Vertigo—Irinotecan—colon cancer	0.00018	0.003	CcSEcCtD
Furosemide—Leukopenia—Irinotecan—colon cancer	0.000179	0.00299	CcSEcCtD
Furosemide—Anaemia—Fluorouracil—colon cancer	0.000177	0.00295	CcSEcCtD
Furosemide—Dermatitis exfoliative—Methotrexate—colon cancer	0.000176	0.00292	CcSEcCtD
Furosemide—Photosensitivity reaction—Capecitabine—colon cancer	0.000176	0.00292	CcSEcCtD
Furosemide—Hyperglycaemia—Capecitabine—colon cancer	0.000173	0.00289	CcSEcCtD
Furosemide—Leukopenia—Fluorouracil—colon cancer	0.000172	0.00286	CcSEcCtD
Furosemide—CA12—Metabolism—CA7—colon cancer	0.000171	0.00203	CbGpPWpGaD
Furosemide—Anaphylactoid reaction—Methotrexate—colon cancer	0.000171	0.00285	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.00017	0.00283	CcSEcCtD
Furosemide—Lethargy—Methotrexate—colon cancer	0.000169	0.00282	CcSEcCtD
Furosemide—Renal failure—Capecitabine—colon cancer	0.000169	0.00281	CcSEcCtD
Furosemide—Anaphylactic shock—Vincristine—colon cancer	0.000168	0.00279	CcSEcCtD
Furosemide—CA2—lymph node—colon cancer	0.000167	0.00485	CbGeAlD
Furosemide—Confusional state—Irinotecan—colon cancer	0.000165	0.00274	CcSEcCtD
Furosemide—Nervous system disorder—Vincristine—colon cancer	0.000165	0.00274	CcSEcCtD
Furosemide—SLC22A5—lymph node—colon cancer	0.000164	0.00477	CbGeAlD
Furosemide—Thrombocytopenia—Vincristine—colon cancer	0.000164	0.00274	CcSEcCtD
Furosemide—Anaphylactic shock—Irinotecan—colon cancer	0.000163	0.00272	CcSEcCtD
Furosemide—Hyperhidrosis—Vincristine—colon cancer	0.000162	0.0027	CcSEcCtD
Furosemide—Hepatobiliary disease—Capecitabine—colon cancer	0.000162	0.0027	CcSEcCtD
Furosemide—Shock—Irinotecan—colon cancer	0.000161	0.00268	CcSEcCtD
Furosemide—Nervous system disorder—Irinotecan—colon cancer	0.00016	0.00267	CcSEcCtD
Furosemide—Agranulocytosis—Capecitabine—colon cancer	0.00016	0.00267	CcSEcCtD
Furosemide—Thrombocytopenia—Irinotecan—colon cancer	0.00016	0.00266	CcSEcCtD
Furosemide—Anorexia—Vincristine—colon cancer	0.00016	0.00266	CcSEcCtD
Furosemide—Irritability—Methotrexate—colon cancer	0.000158	0.00263	CcSEcCtD
Furosemide—Hyperhidrosis—Irinotecan—colon cancer	0.000158	0.00263	CcSEcCtD
Furosemide—Confusional state—Fluorouracil—colon cancer	0.000158	0.00263	CcSEcCtD
Furosemide—Hypotension—Vincristine—colon cancer	0.000157	0.00261	CcSEcCtD
Furosemide—Anaphylactic shock—Fluorouracil—colon cancer	0.000157	0.00261	CcSEcCtD
Furosemide—Anorexia—Irinotecan—colon cancer	0.000156	0.00259	CcSEcCtD
Furosemide—ALB—FOXA2 and FOXA3 transcription factor networks—HNF4A—colon cancer	0.000154	0.00182	CbGpPWpGaD
Furosemide—Nervous system disorder—Fluorouracil—colon cancer	0.000153	0.00256	CcSEcCtD
Furosemide—Thrombocytopenia—Fluorouracil—colon cancer	0.000153	0.00255	CcSEcCtD
Furosemide—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000153	0.00181	CbGpPWpGaD
Furosemide—Hypotension—Irinotecan—colon cancer	0.000153	0.00254	CcSEcCtD
Furosemide—Urinary tract disorder—Capecitabine—colon cancer	0.000152	0.00253	CcSEcCtD
Furosemide—Urethral disorder—Capecitabine—colon cancer	0.000151	0.00251	CcSEcCtD
Furosemide—Paraesthesia—Vincristine—colon cancer	0.000151	0.00251	CcSEcCtD
Furosemide—Anorexia—Fluorouracil—colon cancer	0.000149	0.00248	CcSEcCtD
Furosemide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000149	0.00248	CcSEcCtD
Furosemide—Visual impairment—Capecitabine—colon cancer	0.000148	0.00247	CcSEcCtD
Furosemide—Paraesthesia—Irinotecan—colon cancer	0.000147	0.00244	CcSEcCtD
Furosemide—Hypotension—Fluorouracil—colon cancer	0.000146	0.00244	CcSEcCtD
Furosemide—Decreased appetite—Vincristine—colon cancer	0.000146	0.00243	CcSEcCtD
Furosemide—Erythema multiforme—Capecitabine—colon cancer	0.000146	0.00242	CcSEcCtD
Furosemide—Somnolence—Irinotecan—colon cancer	0.000145	0.00242	CcSEcCtD
Furosemide—Gastrointestinal disorder—Vincristine—colon cancer	0.000145	0.00241	CcSEcCtD
Furosemide—Fatigue—Vincristine—colon cancer	0.000145	0.00241	CcSEcCtD
Furosemide—Eye disorder—Capecitabine—colon cancer	0.000144	0.0024	CcSEcCtD
Furosemide—Tinnitus—Capecitabine—colon cancer	0.000144	0.00239	CcSEcCtD
Furosemide—Pain—Vincristine—colon cancer	0.000143	0.00239	CcSEcCtD
Furosemide—Constipation—Vincristine—colon cancer	0.000143	0.00239	CcSEcCtD
Furosemide—Decreased appetite—Irinotecan—colon cancer	0.000142	0.00237	CcSEcCtD
Furosemide—Eosinophilia—Methotrexate—colon cancer	0.000142	0.00236	CcSEcCtD
Furosemide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000141	0.00235	CcSEcCtD
Furosemide—Fatigue—Irinotecan—colon cancer	0.000141	0.00235	CcSEcCtD
Furosemide—Paraesthesia—Fluorouracil—colon cancer	0.000141	0.00234	CcSEcCtD
Furosemide—Pancreatitis—Methotrexate—colon cancer	0.00014	0.00234	CcSEcCtD
Furosemide—Pain—Irinotecan—colon cancer	0.00014	0.00233	CcSEcCtD
Furosemide—Constipation—Irinotecan—colon cancer	0.00014	0.00233	CcSEcCtD
Furosemide—Angiopathy—Capecitabine—colon cancer	0.00014	0.00233	CcSEcCtD
Furosemide—Somnolence—Fluorouracil—colon cancer	0.000139	0.00232	CcSEcCtD
Furosemide—Immune system disorder—Capecitabine—colon cancer	0.000139	0.00232	CcSEcCtD
Furosemide—PGD—Disease—LGR5—colon cancer	0.000138	0.00164	CbGpPWpGaD
Furosemide—PGD—Disease—CHST5—colon cancer	0.000138	0.00164	CbGpPWpGaD
Furosemide—Arrhythmia—Capecitabine—colon cancer	0.000138	0.00229	CcSEcCtD
Furosemide—Gastrointestinal pain—Vincristine—colon cancer	0.000137	0.00229	CcSEcCtD
Furosemide—CA4—Metabolism—CA7—colon cancer	0.000137	0.00162	CbGpPWpGaD
Furosemide—Decreased appetite—Fluorouracil—colon cancer	0.000136	0.00227	CcSEcCtD
Furosemide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000135	0.00225	CcSEcCtD
Furosemide—Feeling abnormal—Irinotecan—colon cancer	0.000135	0.00224	CcSEcCtD
Furosemide—Erythema—Capecitabine—colon cancer	0.000134	0.00223	CcSEcCtD
Furosemide—Malnutrition—Capecitabine—colon cancer	0.000134	0.00223	CcSEcCtD
Furosemide—Pain—Fluorouracil—colon cancer	0.000134	0.00223	CcSEcCtD
Furosemide—Gastrointestinal pain—Irinotecan—colon cancer	0.000134	0.00223	CcSEcCtD
Furosemide—Body temperature increased—Vincristine—colon cancer	0.000133	0.00221	CcSEcCtD
Furosemide—Abdominal pain—Vincristine—colon cancer	0.000133	0.00221	CcSEcCtD
Furosemide—Flatulence—Capecitabine—colon cancer	0.000132	0.0022	CcSEcCtD
Furosemide—Dysgeusia—Capecitabine—colon cancer	0.000131	0.00219	CcSEcCtD
Furosemide—CA2—Metabolism—CA7—colon cancer	0.000131	0.00155	CbGpPWpGaD
Furosemide—Photosensitivity reaction—Methotrexate—colon cancer	0.000131	0.00218	CcSEcCtD
Furosemide—Body temperature increased—Irinotecan—colon cancer	0.000129	0.00215	CcSEcCtD
Furosemide—Abdominal pain—Irinotecan—colon cancer	0.000129	0.00215	CcSEcCtD
Furosemide—Feeling abnormal—Fluorouracil—colon cancer	0.000129	0.00215	CcSEcCtD
Furosemide—Muscle spasms—Capecitabine—colon cancer	0.000129	0.00215	CcSEcCtD
Furosemide—Drowsiness—Methotrexate—colon cancer	0.000128	0.00213	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000127	0.00211	CcSEcCtD
Furosemide—Vision blurred—Capecitabine—colon cancer	0.000126	0.0021	CcSEcCtD
Furosemide—CA1—Metabolism—CA7—colon cancer	0.000125	0.00149	CbGpPWpGaD
Furosemide—Renal failure—Methotrexate—colon cancer	0.000125	0.00209	CcSEcCtD
Furosemide—Urticaria—Fluorouracil—colon cancer	0.000124	0.00207	CcSEcCtD
Furosemide—Anaemia—Capecitabine—colon cancer	0.000124	0.00206	CcSEcCtD
Furosemide—Body temperature increased—Fluorouracil—colon cancer	0.000124	0.00206	CcSEcCtD
Furosemide—Hypersensitivity—Vincristine—colon cancer	0.000124	0.00206	CcSEcCtD
Furosemide—CA14—Metabolism—CHST5—colon cancer	0.000123	0.00146	CbGpPWpGaD
Furosemide—CA14—Metabolism—ODC1—colon cancer	0.000123	0.00146	CbGpPWpGaD
Furosemide—Sweating—Methotrexate—colon cancer	0.000122	0.00204	CcSEcCtD
Furosemide—Hepatobiliary disease—Methotrexate—colon cancer	0.000121	0.00201	CcSEcCtD
Furosemide—Vertigo—Capecitabine—colon cancer	0.00012	0.00201	CcSEcCtD
Furosemide—Hypersensitivity—Irinotecan—colon cancer	0.00012	0.00201	CcSEcCtD
Furosemide—Asthenia—Vincristine—colon cancer	0.00012	0.00201	CcSEcCtD
Furosemide—Leukopenia—Capecitabine—colon cancer	0.00012	0.002	CcSEcCtD
Furosemide—CA5A—Metabolism—ODC1—colon cancer	0.00012	0.00142	CbGpPWpGaD
Furosemide—CA5A—Metabolism—CHST5—colon cancer	0.00012	0.00142	CbGpPWpGaD
Furosemide—CA6—Metabolism—CHST5—colon cancer	0.00012	0.00142	CbGpPWpGaD
Furosemide—CA6—Metabolism—ODC1—colon cancer	0.00012	0.00142	CbGpPWpGaD
Furosemide—Agranulocytosis—Methotrexate—colon cancer	0.000119	0.00198	CcSEcCtD
Furosemide—Asthenia—Irinotecan—colon cancer	0.000117	0.00195	CcSEcCtD
Furosemide—PGD—Metabolism—ODC1—colon cancer	0.000116	0.00137	CbGpPWpGaD
Furosemide—PGD—Metabolism—CHST5—colon cancer	0.000116	0.00137	CbGpPWpGaD
Furosemide—Hypersensitivity—Fluorouracil—colon cancer	0.000115	0.00192	CcSEcCtD
Furosemide—Diarrhoea—Vincristine—colon cancer	0.000115	0.00191	CcSEcCtD
Furosemide—CA1—C-MYB transcription factor network—PTGS2—colon cancer	0.000114	0.00135	CbGpPWpGaD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000113	0.00189	CcSEcCtD
Furosemide—Urinary tract disorder—Methotrexate—colon cancer	0.000113	0.00188	CcSEcCtD
Furosemide—Urethral disorder—Methotrexate—colon cancer	0.000112	0.00187	CcSEcCtD
Furosemide—CA5B—Metabolism—ODC1—colon cancer	0.000112	0.00133	CbGpPWpGaD
Furosemide—CA5B—Metabolism—CHST5—colon cancer	0.000112	0.00133	CbGpPWpGaD
Furosemide—CA7—Metabolism—CHST5—colon cancer	0.000112	0.00133	CbGpPWpGaD
Furosemide—CA7—Metabolism—ODC1—colon cancer	0.000112	0.00133	CbGpPWpGaD
Furosemide—Diarrhoea—Irinotecan—colon cancer	0.000112	0.00186	CcSEcCtD
Furosemide—Dry mouth—Capecitabine—colon cancer	0.000112	0.00186	CcSEcCtD
Furosemide—Dizziness—Vincristine—colon cancer	0.000111	0.00185	CcSEcCtD
Furosemide—Pruritus—Fluorouracil—colon cancer	0.000111	0.00184	CcSEcCtD
Furosemide—Visual impairment—Methotrexate—colon cancer	0.00011	0.00184	CcSEcCtD
Furosemide—CA9—Metabolism—CA7—colon cancer	0.00011	0.00131	CbGpPWpGaD
Furosemide—Confusional state—Capecitabine—colon cancer	0.00011	0.00184	CcSEcCtD
Furosemide—Erythema multiforme—Methotrexate—colon cancer	0.000108	0.0018	CcSEcCtD
Furosemide—Dizziness—Irinotecan—colon cancer	0.000108	0.0018	CcSEcCtD
Furosemide—Shock—Capecitabine—colon cancer	0.000108	0.00179	CcSEcCtD
Furosemide—Nervous system disorder—Capecitabine—colon cancer	0.000107	0.00179	CcSEcCtD
Furosemide—Eye disorder—Methotrexate—colon cancer	0.000107	0.00178	CcSEcCtD
Furosemide—Diarrhoea—Fluorouracil—colon cancer	0.000107	0.00178	CcSEcCtD
Furosemide—Thrombocytopenia—Capecitabine—colon cancer	0.000107	0.00178	CcSEcCtD
Furosemide—Tinnitus—Methotrexate—colon cancer	0.000107	0.00178	CcSEcCtD
Furosemide—Vomiting—Vincristine—colon cancer	0.000107	0.00178	CcSEcCtD
Furosemide—Skin disorder—Capecitabine—colon cancer	0.000106	0.00177	CcSEcCtD
Furosemide—Rash—Vincristine—colon cancer	0.000106	0.00176	CcSEcCtD
Furosemide—Hyperhidrosis—Capecitabine—colon cancer	0.000106	0.00176	CcSEcCtD
Furosemide—Dermatitis—Vincristine—colon cancer	0.000106	0.00176	CcSEcCtD
Furosemide—Headache—Vincristine—colon cancer	0.000105	0.00175	CcSEcCtD
Furosemide—Anorexia—Capecitabine—colon cancer	0.000104	0.00174	CcSEcCtD
Furosemide—Angiopathy—Methotrexate—colon cancer	0.000104	0.00173	CcSEcCtD
Furosemide—Vomiting—Irinotecan—colon cancer	0.000104	0.00173	CcSEcCtD
Furosemide—CA12—Metabolism—CHST5—colon cancer	0.000104	0.00123	CbGpPWpGaD
Furosemide—CA12—Metabolism—ODC1—colon cancer	0.000104	0.00123	CbGpPWpGaD
Furosemide—Immune system disorder—Methotrexate—colon cancer	0.000104	0.00172	CcSEcCtD
Furosemide—Dizziness—Fluorouracil—colon cancer	0.000103	0.00172	CcSEcCtD
Furosemide—CA1—C-MYB transcription factor network—CCND1—colon cancer	0.000103	0.00122	CbGpPWpGaD
Furosemide—Rash—Irinotecan—colon cancer	0.000103	0.00172	CcSEcCtD
Furosemide—Dermatitis—Irinotecan—colon cancer	0.000103	0.00171	CcSEcCtD
Furosemide—Headache—Irinotecan—colon cancer	0.000102	0.00171	CcSEcCtD
Furosemide—Hypotension—Capecitabine—colon cancer	0.000102	0.0017	CcSEcCtD
Furosemide—CA9—HIF-1-alpha transcription factor network—EP300—colon cancer	0.000101	0.0012	CbGpPWpGaD
Furosemide—Erythema—Methotrexate—colon cancer	9.98e-05	0.00166	CcSEcCtD
Furosemide—Malnutrition—Methotrexate—colon cancer	9.98e-05	0.00166	CcSEcCtD
Furosemide—CA1—C-MYB transcription factor network—CDKN1A—colon cancer	9.97e-05	0.00118	CbGpPWpGaD
Furosemide—Nausea—Vincristine—colon cancer	9.97e-05	0.00166	CcSEcCtD
Furosemide—Vomiting—Fluorouracil—colon cancer	9.95e-05	0.00166	CcSEcCtD
Furosemide—PGD—Disease—AXIN2—colon cancer	9.93e-05	0.00118	CbGpPWpGaD
Furosemide—Rash—Fluorouracil—colon cancer	9.87e-05	0.00164	CcSEcCtD
Furosemide—Dermatitis—Fluorouracil—colon cancer	9.86e-05	0.00164	CcSEcCtD
Furosemide—Paraesthesia—Capecitabine—colon cancer	9.82e-05	0.00164	CcSEcCtD
Furosemide—Headache—Fluorouracil—colon cancer	9.8e-05	0.00163	CcSEcCtD
Furosemide—Dysgeusia—Methotrexate—colon cancer	9.77e-05	0.00163	CcSEcCtD
Furosemide—Nausea—Irinotecan—colon cancer	9.71e-05	0.00162	CcSEcCtD
Furosemide—CA9—HIF-1-alpha transcription factor network—VEGFA—colon cancer	9.58e-05	0.00114	CbGpPWpGaD
Furosemide—Decreased appetite—Capecitabine—colon cancer	9.51e-05	0.00158	CcSEcCtD
Furosemide—CA1—C-MYB transcription factor network—EP300—colon cancer	9.49e-05	0.00113	CbGpPWpGaD
Furosemide—Gastrointestinal disorder—Capecitabine—colon cancer	9.44e-05	0.00157	CcSEcCtD
Furosemide—Fatigue—Capecitabine—colon cancer	9.43e-05	0.00157	CcSEcCtD
Furosemide—Vision blurred—Methotrexate—colon cancer	9.4e-05	0.00157	CcSEcCtD
Furosemide—Pain—Capecitabine—colon cancer	9.35e-05	0.00156	CcSEcCtD
Furosemide—Constipation—Capecitabine—colon cancer	9.35e-05	0.00156	CcSEcCtD
Furosemide—Nausea—Fluorouracil—colon cancer	9.3e-05	0.00155	CcSEcCtD
Furosemide—Anaemia—Methotrexate—colon cancer	9.22e-05	0.00154	CcSEcCtD
Furosemide—Feeling abnormal—Capecitabine—colon cancer	9.01e-05	0.0015	CcSEcCtD
Furosemide—Vertigo—Methotrexate—colon cancer	8.96e-05	0.00149	CcSEcCtD
Furosemide—Gastrointestinal pain—Capecitabine—colon cancer	8.94e-05	0.00149	CcSEcCtD
Furosemide—Leukopenia—Methotrexate—colon cancer	8.93e-05	0.00149	CcSEcCtD
Furosemide—CA1—C-MYB transcription factor network—NRAS—colon cancer	8.88e-05	0.00105	CbGpPWpGaD
Furosemide—Urticaria—Capecitabine—colon cancer	8.69e-05	0.00145	CcSEcCtD
Furosemide—Abdominal pain—Capecitabine—colon cancer	8.65e-05	0.00144	CcSEcCtD
Furosemide—Body temperature increased—Capecitabine—colon cancer	8.65e-05	0.00144	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	8.43e-05	0.0014	CcSEcCtD
Furosemide—CA4—Metabolism—ODC1—colon cancer	8.27e-05	0.000982	CbGpPWpGaD
Furosemide—CA4—Metabolism—CHST5—colon cancer	8.27e-05	0.000982	CbGpPWpGaD
Furosemide—CA1—C-MYB transcription factor network—MYC—colon cancer	8.27e-05	0.000981	CbGpPWpGaD
Furosemide—Confusional state—Methotrexate—colon cancer	8.21e-05	0.00137	CcSEcCtD
Furosemide—Anaphylactic shock—Methotrexate—colon cancer	8.14e-05	0.00136	CcSEcCtD
Furosemide—PGD—NRF2 pathway—TGFB1—colon cancer	8.07e-05	0.000957	CbGpPWpGaD
Furosemide—Hypersensitivity—Capecitabine—colon cancer	8.06e-05	0.00134	CcSEcCtD
Furosemide—Nervous system disorder—Methotrexate—colon cancer	7.98e-05	0.00133	CcSEcCtD
Furosemide—Thrombocytopenia—Methotrexate—colon cancer	7.97e-05	0.00133	CcSEcCtD
Furosemide—CA2—Metabolism—ODC1—colon cancer	7.93e-05	0.000941	CbGpPWpGaD
Furosemide—CA2—Metabolism—CHST5—colon cancer	7.93e-05	0.000941	CbGpPWpGaD
Furosemide—Skin disorder—Methotrexate—colon cancer	7.91e-05	0.00132	CcSEcCtD
Furosemide—Hyperhidrosis—Methotrexate—colon cancer	7.87e-05	0.00131	CcSEcCtD
Furosemide—Asthenia—Capecitabine—colon cancer	7.85e-05	0.00131	CcSEcCtD
Furosemide—Anorexia—Methotrexate—colon cancer	7.76e-05	0.00129	CcSEcCtD
Furosemide—Pruritus—Capecitabine—colon cancer	7.74e-05	0.00129	CcSEcCtD
Furosemide—CA1—C-MYB transcription factor network—KRAS—colon cancer	7.64e-05	0.000907	CbGpPWpGaD
Furosemide—Hypotension—Methotrexate—colon cancer	7.61e-05	0.00127	CcSEcCtD
Furosemide—CA1—Metabolism—CHST5—colon cancer	7.6e-05	0.000902	CbGpPWpGaD
Furosemide—CA1—Metabolism—ODC1—colon cancer	7.6e-05	0.000902	CbGpPWpGaD
Furosemide—Diarrhoea—Capecitabine—colon cancer	7.48e-05	0.00125	CcSEcCtD
Furosemide—Paraesthesia—Methotrexate—colon cancer	7.31e-05	0.00122	CcSEcCtD
Furosemide—Somnolence—Methotrexate—colon cancer	7.24e-05	0.00121	CcSEcCtD
Furosemide—Dizziness—Capecitabine—colon cancer	7.23e-05	0.0012	CcSEcCtD
Furosemide—SLCO2A1—Transmembrane transport of small molecules—ABCB1—colon cancer	7.14e-05	0.000847	CbGpPWpGaD
Furosemide—Decreased appetite—Methotrexate—colon cancer	7.08e-05	0.00118	CcSEcCtD
Furosemide—Gastrointestinal disorder—Methotrexate—colon cancer	7.03e-05	0.00117	CcSEcCtD
Furosemide—Fatigue—Methotrexate—colon cancer	7.02e-05	0.00117	CcSEcCtD
Furosemide—Pain—Methotrexate—colon cancer	6.96e-05	0.00116	CcSEcCtD
Furosemide—Vomiting—Capecitabine—colon cancer	6.95e-05	0.00116	CcSEcCtD
Furosemide—Rash—Capecitabine—colon cancer	6.9e-05	0.00115	CcSEcCtD
Furosemide—Dermatitis—Capecitabine—colon cancer	6.89e-05	0.00115	CcSEcCtD
Furosemide—Headache—Capecitabine—colon cancer	6.85e-05	0.00114	CcSEcCtD
Furosemide—Feeling abnormal—Methotrexate—colon cancer	6.71e-05	0.00112	CcSEcCtD
Furosemide—CA9—Metabolism—CHST5—colon cancer	6.68e-05	0.000793	CbGpPWpGaD
Furosemide—CA9—Metabolism—ODC1—colon cancer	6.68e-05	0.000793	CbGpPWpGaD
Furosemide—Gastrointestinal pain—Methotrexate—colon cancer	6.66e-05	0.00111	CcSEcCtD
Furosemide—Nausea—Capecitabine—colon cancer	6.5e-05	0.00108	CcSEcCtD
Furosemide—CA1—C-MYB transcription factor network—HRAS—colon cancer	6.49e-05	0.000771	CbGpPWpGaD
Furosemide—Urticaria—Methotrexate—colon cancer	6.47e-05	0.00108	CcSEcCtD
Furosemide—Body temperature increased—Methotrexate—colon cancer	6.44e-05	0.00107	CcSEcCtD
Furosemide—Abdominal pain—Methotrexate—colon cancer	6.44e-05	0.00107	CcSEcCtD
Furosemide—CA9—HIF-1-alpha transcription factor network—AKT1—colon cancer	6.11e-05	0.000726	CbGpPWpGaD
Furosemide—Hypersensitivity—Methotrexate—colon cancer	6e-05	0.000999	CcSEcCtD
Furosemide—SLC12A1—Transmembrane transport of small molecules—ABCB1—colon cancer	5.96e-05	0.000707	CbGpPWpGaD
Furosemide—Asthenia—Methotrexate—colon cancer	5.84e-05	0.000973	CcSEcCtD
Furosemide—Pruritus—Methotrexate—colon cancer	5.76e-05	0.000959	CcSEcCtD
Furosemide—Diarrhoea—Methotrexate—colon cancer	5.57e-05	0.000928	CcSEcCtD
Furosemide—Dizziness—Methotrexate—colon cancer	5.38e-05	0.000897	CcSEcCtD
Furosemide—Vomiting—Methotrexate—colon cancer	5.18e-05	0.000862	CcSEcCtD
Furosemide—Rash—Methotrexate—colon cancer	5.13e-05	0.000855	CcSEcCtD
Furosemide—Dermatitis—Methotrexate—colon cancer	5.13e-05	0.000854	CcSEcCtD
Furosemide—Headache—Methotrexate—colon cancer	5.1e-05	0.00085	CcSEcCtD
Furosemide—Nausea—Methotrexate—colon cancer	4.84e-05	0.000805	CcSEcCtD
Furosemide—SLC22A11—Transmembrane transport of small molecules—ABCB1—colon cancer	3.55e-05	0.000422	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—CDKN1A—colon cancer	3.51e-05	0.000416	CbGpPWpGaD
Furosemide—ALB—Metabolism—CA7—colon cancer	3.44e-05	0.000408	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—EP300—colon cancer	3.34e-05	0.000396	CbGpPWpGaD
Furosemide—CA14—Metabolism—ABCB1—colon cancer	3.25e-05	0.000386	CbGpPWpGaD
Furosemide—CA14—Metabolism—TYMS—colon cancer	3.19e-05	0.000379	CbGpPWpGaD
Furosemide—CA6—Metabolism—ABCB1—colon cancer	3.17e-05	0.000376	CbGpPWpGaD
Furosemide—CA5A—Metabolism—ABCB1—colon cancer	3.17e-05	0.000376	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—VEGFA—colon cancer	3.16e-05	0.000375	CbGpPWpGaD
Furosemide—CA6—Metabolism—TYMS—colon cancer	3.11e-05	0.000369	CbGpPWpGaD
Furosemide—CA5A—Metabolism—TYMS—colon cancer	3.11e-05	0.000369	CbGpPWpGaD
Furosemide—PGD—Metabolism—ABCB1—colon cancer	3.06e-05	0.000363	CbGpPWpGaD
Furosemide—ALB—Selenium Micronutrient Network—PTGS2—colon cancer	3.01e-05	0.000358	CbGpPWpGaD
Furosemide—PGD—Metabolism—TYMS—colon cancer	3e-05	0.000356	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—ABCB1—colon cancer	3e-05	0.000356	CbGpPWpGaD
Furosemide—CA7—Metabolism—ABCB1—colon cancer	2.96e-05	0.000351	CbGpPWpGaD
Furosemide—CA5B—Metabolism—ABCB1—colon cancer	2.96e-05	0.000351	CbGpPWpGaD
Furosemide—CA5B—Metabolism—TYMS—colon cancer	2.91e-05	0.000345	CbGpPWpGaD
Furosemide—CA7—Metabolism—TYMS—colon cancer	2.91e-05	0.000345	CbGpPWpGaD
Furosemide—PGD—Disease—FGFR3—colon cancer	2.87e-05	0.00034	CbGpPWpGaD
Furosemide—CA12—Metabolism—ABCB1—colon cancer	2.74e-05	0.000325	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—ABCB1—colon cancer	2.71e-05	0.000322	CbGpPWpGaD
Furosemide—ABCC2—NRF2 pathway—TGFB1—colon cancer	2.71e-05	0.000321	CbGpPWpGaD
Furosemide—CA12—Metabolism—TYMS—colon cancer	2.69e-05	0.00032	CbGpPWpGaD
Furosemide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	2.64e-05	0.000313	CbGpPWpGaD
Furosemide—PGD—Disease—APC—colon cancer	2.63e-05	0.000312	CbGpPWpGaD
Furosemide—ALB—Platelet degranulation—VEGFA—colon cancer	2.56e-05	0.000304	CbGpPWpGaD
Furosemide—PGD—Disease—BRAF—colon cancer	2.47e-05	0.000294	CbGpPWpGaD
Furosemide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—colon cancer	2.44e-05	0.00029	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—TP53—colon cancer	2.39e-05	0.000283	CbGpPWpGaD
Furosemide—ALB—Platelet degranulation—TGFB1—colon cancer	2.35e-05	0.000279	CbGpPWpGaD
Furosemide—CA14—Metabolism—PPARG—colon cancer	2.26e-05	0.000269	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—ABCB1—colon cancer	2.26e-05	0.000269	CbGpPWpGaD
Furosemide—ALB—Folate Metabolism—TP53—colon cancer	2.26e-05	0.000268	CbGpPWpGaD
Furosemide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	2.24e-05	0.000266	CbGpPWpGaD
Furosemide—CA6—Metabolism—PPARG—colon cancer	2.2e-05	0.000262	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PPARG—colon cancer	2.2e-05	0.000262	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—ABCB1—colon cancer	2.19e-05	0.00026	CbGpPWpGaD
Furosemide—CA4—Metabolism—ABCB1—colon cancer	2.19e-05	0.000259	CbGpPWpGaD
Furosemide—CA4—Metabolism—TYMS—colon cancer	2.15e-05	0.000255	CbGpPWpGaD
Furosemide—PGD—Metabolism—PPARG—colon cancer	2.13e-05	0.000252	CbGpPWpGaD
Furosemide—CA2—Metabolism—ABCB1—colon cancer	2.1e-05	0.000249	CbGpPWpGaD
Furosemide—ALB—Metabolism—CHST5—colon cancer	2.08e-05	0.000247	CbGpPWpGaD
Furosemide—ALB—Metabolism—ODC1—colon cancer	2.08e-05	0.000247	CbGpPWpGaD
Furosemide—CA7—Metabolism—PPARG—colon cancer	2.06e-05	0.000244	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PPARG—colon cancer	2.06e-05	0.000244	CbGpPWpGaD
Furosemide—CA2—Metabolism—TYMS—colon cancer	2.06e-05	0.000244	CbGpPWpGaD
Furosemide—CA1—Metabolism—ABCB1—colon cancer	2.01e-05	0.000238	CbGpPWpGaD
Furosemide—PGD—Disease—PTGS2—colon cancer	2e-05	0.000237	CbGpPWpGaD
Furosemide—CA1—Metabolism—TYMS—colon cancer	1.97e-05	0.000234	CbGpPWpGaD
Furosemide—CA12—Metabolism—PPARG—colon cancer	1.91e-05	0.000226	CbGpPWpGaD
Furosemide—PGD—Disease—CTNNB1—colon cancer	1.79e-05	0.000212	CbGpPWpGaD
Furosemide—CA14—Metabolism—PTGS2—colon cancer	1.78e-05	0.000211	CbGpPWpGaD
Furosemide—CA9—Metabolism—ABCB1—colon cancer	1.77e-05	0.00021	CbGpPWpGaD
Furosemide—PGD—Disease—CDKN1A—colon cancer	1.75e-05	0.000207	CbGpPWpGaD
Furosemide—CA9—Metabolism—TYMS—colon cancer	1.73e-05	0.000206	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PTGS2—colon cancer	1.73e-05	0.000206	CbGpPWpGaD
Furosemide—CA6—Metabolism—PTGS2—colon cancer	1.73e-05	0.000206	CbGpPWpGaD
Furosemide—PGD—Metabolism—PTGS2—colon cancer	1.67e-05	0.000199	CbGpPWpGaD
Furosemide—PGD—Disease—EP300—colon cancer	1.66e-05	0.000197	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PTGS2—colon cancer	1.62e-05	0.000192	CbGpPWpGaD
Furosemide—CA7—Metabolism—PTGS2—colon cancer	1.62e-05	0.000192	CbGpPWpGaD
Furosemide—PGD—Disease—SRC—colon cancer	1.62e-05	0.000192	CbGpPWpGaD
Furosemide—PGD—Disease—NRAS—colon cancer	1.55e-05	0.000185	CbGpPWpGaD
Furosemide—CA4—Metabolism—PPARG—colon cancer	1.52e-05	0.000181	CbGpPWpGaD
Furosemide—CA12—Metabolism—PTGS2—colon cancer	1.5e-05	0.000178	CbGpPWpGaD
Furosemide—CA14—Metabolism—EP300—colon cancer	1.48e-05	0.000176	CbGpPWpGaD
Furosemide—CA2—Metabolism—PPARG—colon cancer	1.46e-05	0.000173	CbGpPWpGaD
Furosemide—PGD—Disease—MYC—colon cancer	1.45e-05	0.000172	CbGpPWpGaD
Furosemide—PGD—Disease—TGFB1—colon cancer	1.44e-05	0.000171	CbGpPWpGaD
Furosemide—CA6—Metabolism—EP300—colon cancer	1.44e-05	0.000171	CbGpPWpGaD
Furosemide—CA5A—Metabolism—EP300—colon cancer	1.44e-05	0.000171	CbGpPWpGaD
Furosemide—PGD—Disease—EGFR—colon cancer	1.42e-05	0.000168	CbGpPWpGaD
Furosemide—CA1—Metabolism—PPARG—colon cancer	1.4e-05	0.000166	CbGpPWpGaD
Furosemide—PGD—Metabolism—EP300—colon cancer	1.39e-05	0.000165	CbGpPWpGaD
Furosemide—CA7—Metabolism—EP300—colon cancer	1.35e-05	0.00016	CbGpPWpGaD
Furosemide—CA5B—Metabolism—EP300—colon cancer	1.35e-05	0.00016	CbGpPWpGaD
Furosemide—PGD—Disease—KRAS—colon cancer	1.34e-05	0.000159	CbGpPWpGaD
Furosemide—CA12—Metabolism—EP300—colon cancer	1.25e-05	0.000148	CbGpPWpGaD
Furosemide—PGD—Disease—PIK3CA—colon cancer	1.23e-05	0.000146	CbGpPWpGaD
Furosemide—CA9—Metabolism—PPARG—colon cancer	1.23e-05	0.000146	CbGpPWpGaD
Furosemide—CA4—Metabolism—PTGS2—colon cancer	1.2e-05	0.000142	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	1.18e-05	0.00014	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	1.17e-05	0.000138	CbGpPWpGaD
Furosemide—CA2—Metabolism—PTGS2—colon cancer	1.15e-05	0.000136	CbGpPWpGaD
Furosemide—PGD—Disease—HRAS—colon cancer	1.14e-05	0.000135	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	1.14e-05	0.000135	CbGpPWpGaD
Furosemide—CA1—Metabolism—PTGS2—colon cancer	1.1e-05	0.000131	CbGpPWpGaD
Furosemide—CA14—Metabolism—PIK3CA—colon cancer	1.09e-05	0.00013	CbGpPWpGaD
Furosemide—CA6—Metabolism—PIK3CA—colon cancer	1.07e-05	0.000127	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PIK3CA—colon cancer	1.07e-05	0.000127	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	1.04e-05	0.000124	CbGpPWpGaD
Furosemide—PGD—Metabolism—PIK3CA—colon cancer	1.03e-05	0.000122	CbGpPWpGaD
Furosemide—PGD—Disease—AKT1—colon cancer	1e-05	0.000119	CbGpPWpGaD
Furosemide—CA7—Metabolism—PIK3CA—colon cancer	9.96e-06	0.000118	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PIK3CA—colon cancer	9.96e-06	0.000118	CbGpPWpGaD
Furosemide—CA4—Metabolism—EP300—colon cancer	9.95e-06	0.000118	CbGpPWpGaD
Furosemide—CA9—Metabolism—PTGS2—colon cancer	9.67e-06	0.000115	CbGpPWpGaD
Furosemide—CA2—Metabolism—EP300—colon cancer	9.54e-06	0.000113	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CA—colon cancer	9.23e-06	0.00011	CbGpPWpGaD
Furosemide—CA1—Metabolism—EP300—colon cancer	9.14e-06	0.000109	CbGpPWpGaD
Furosemide—CA14—Metabolism—AKT1—colon cancer	8.94e-06	0.000106	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	8.87e-06	0.000105	CbGpPWpGaD
Furosemide—CA6—Metabolism—AKT1—colon cancer	8.72e-06	0.000103	CbGpPWpGaD
Furosemide—CA5A—Metabolism—AKT1—colon cancer	8.72e-06	0.000103	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	8.6e-06	0.000102	CbGpPWpGaD
Furosemide—PGD—Metabolism—AKT1—colon cancer	8.41e-06	9.98e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—AKT1—colon cancer	8.14e-06	9.66e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—AKT1—colon cancer	8.14e-06	9.66e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—EP300—colon cancer	8.04e-06	9.54e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—AKT1—colon cancer	7.54e-06	8.95e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CA—colon cancer	7.36e-06	8.74e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	7.25e-06	8.61e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CA—colon cancer	7.06e-06	8.38e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.77e-06	8.03e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CA—colon cancer	6.76e-06	8.03e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—EP300—colon cancer	6.18e-06	7.34e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—SRC—colon cancer	6.01e-06	7.14e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—AKT1—colon cancer	6.01e-06	7.14e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CA—colon cancer	5.95e-06	7.06e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—VEGFA—colon cancer	5.86e-06	6.95e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—NRAS—colon cancer	5.78e-06	6.87e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—AKT1—colon cancer	5.76e-06	6.84e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.63e-06	6.68e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—AKT1—colon cancer	5.53e-06	6.56e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ABCB1—colon cancer	5.51e-06	6.54e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—TYMS—colon cancer	5.41e-06	6.42e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TGFB1—colon cancer	5.38e-06	6.38e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—KRAS—colon cancer	4.98e-06	5.91e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—AKT1—colon cancer	4.86e-06	5.77e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CA—colon cancer	4.57e-06	5.43e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TP53—colon cancer	4.43e-06	5.25e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—HRAS—colon cancer	4.23e-06	5.02e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.16e-06	4.94e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PPARG—colon cancer	3.83e-06	4.55e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—AKT1—colon cancer	3.74e-06	4.44e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTGS2—colon cancer	3.01e-06	3.58e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—EP300—colon cancer	2.51e-06	2.98e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CA—colon cancer	1.85e-06	2.2e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—AKT1—colon cancer	1.52e-06	1.8e-05	CbGpPWpGaD
